New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsComparePancragen vs Palmitoyl Tetrapeptide-7

Pancragen vs Palmitoyl Tetrapeptide-7

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Pancragen
Skin & Cosmetic
Palmitoyl Tetrapeptide-7
Summary
Pancragen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for the pancreas. It supports the function of both exocrine and endocrine pancreatic cells, promotes normalization of insulin secretion from beta cells, and may offer protective effects against pancreatic aging and diabetic progression.
Palmitoyl Tetrapeptide-7 (Rigin) is a cosmetic peptide consisting of palmitic acid linked to the tetrapeptide sequence GQPR (Gly-Gln-Pro-Arg). It was designed to mimic the biological activity of the IgG immunoglobulin C-terminus, which downregulates the production of interleukin-6 (IL-6), a key driver of skin aging and inflammation.
Half-Life
Short (minutes); sustained gene-regulatory effects
Topical penetration-dependent; effects last hours to days
Admin Route
SubQ, Oral
Topical
Research
Typical Dose
10 mg per day
2-5 ppm concentration in formulation
Frequency
Daily for 10–30 days
Twice daily
Key Benefits
  • Supports pancreatic beta cell function and insulin secretion
  • May improve glucose metabolism in early metabolic dysfunction
  • Protective effects on exocrine pancreatic tissue
  • Anti-aging effects on pancreatic cells
  • Potential support in type 2 diabetes management alongside standard care
  • Reduces pancreatic cellular apoptosis from metabolic stress
  • Complementary to GLP-1 agonists in metabolic protocols
  • Reduces IL-6 inflammatory cytokine in skin
  • Prevents 'inflammaging' of the skin
  • Inhibits MMP collagen-degrading enzymes
  • Synergistic with Matrixyl for anti-aging
  • Clinically tested for wrinkle and skin texture improvement
  • Well-tolerated topically
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant hypoglycemic events reported at standard doses as monotherapy
  • Contact sensitization (rare)
  • Well-tolerated at standard concentrations
Stacks With